Possis XMI catheter
This article was originally published in The Gray Sheet
FDA market go-ahead is received for the 4 Fr catheter for removing blood clots from native coronary arteries and coronary bypass grafts. Used with the Minneapolis firm's AngioJet Rheolytic thrombectomy system, the XMI represents the first coronary technological upgrade since March 1999 and includes a lower profile and reduced bleeding risk at the access site, the firm says. The catheter was released for peripheral use in April...
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.